8 74 79 92 100 0 20 40 60 80 100 0 1 4 8 12 16 20 24 38 38 33 25 21 N values Pooled KSI-101 Patients, % Weeks 55 68 91 92 100 0 20 40 60 80 100 0 1 4 8 12 16 20 24 Patients, % Weeks APEX KS1-101 Proportion of patients achieving absence of IRF APEX KS1-101 Proportion of patients achieving absence of SRF Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Includes all data available by the 14-Jul-25 reporting date. 83 38 38 33 25 21 N values Pooled KSI-101 APEX KSI-101 in MESI – the dual IL-6 and VEGF inhibition of KSI-101 seems to provide faster and better disease control, with a clear effect seen as early as Week 1